Skip to main content
Top of the Page

S1PR Modulator Mocravimod Granted Fast Track Designation

FDA

The U.S. Food and Drug Administration has granted Fast Track Designation to mocravimod in combination with allogeneic hematopoietic stem cell transplant for post-remission therapy in patients with acute myeloid leukemia (AML).

Mocravimod is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. S1PR modulators are known to largely reduce egress of T cells from lymphatic tissues. Not being an immunosuppressant, mocravimod maintains the graft-versus-leukemia benefits in patients receiving transplant while inhibiting graft-versus-host disease.

The drug has been assessed in phase I and II trials for safety and tolerability, as well as for efficacy in several autoimmune indications. Mocravimod will be investigated as an adjunctive and maintenance treatment in a phase IIb/III study as a potential treatment for patients with AML receiving transplant.

Source: Priothera Press Release, June 2022

Back to Top